type in your search and press enter
Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting
You May Also Like
BioCryst Announces Mundipharma Receives Approval for Mundesine® in Japan
RESEARCH TRIANGLE PARK, N.C., April 03, 2017 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) ...
Biodesix Raises Add-On to Series G, Enters into Debt Refinancing Agreement with Innovatus Capital Partners
BOULDER, Colo., March 05, 2018 (GLOBE NEWSWIRE) -- Biodesix, Inc., a molecular diagnostics company ...
Precision Therapeutics Projects Meaningful STREAMWAY System Sales in Europe in the Second Half of 2018
MINNEAPOLIS, May 10, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ:AIPT) (“Precision” or “the ...